Persistent free cash flow deficits, including a margin of -199.0% in 2024Q1, indicate a structural inability to fund expansion through internal operations.
Avita Medical Inc. (RCEL) cash flow statement — 30-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Jun'21 | Jun'20 | Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 | Jun'09 | Jun'08 | Jun'07 | Jun'06 | Jun'05 | Jun'04 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | -24.23M | -31.2M | -48.94M | -38.01M | -19.09M | -18.04M | -25.9M | -22.75M | -27.53M | -12.96M | -8.43M | -5.93M | -4.87M | -6.51M | -6.7M | -4.32M | -3.13M | -1.36M | -3.75M | -3.54M | -7.6M | -7.26M | -5.03M | -4.24M | -997.61K | -327.44K | -467.41K | -409.81K | -166.28K | -215.74K | -519.14K |
| Operating CF Margin % | - | -43.56% | -76.17% | -75.81% | -55.46% | -54.62% | -88.61% | -159.48% | -351.66% | -760.03% | -546.6% | -591.65% | -494.35% | -242.47% | -238.05% | -128.76% | -93.78% | -59.42% | -158.32% | -294.42% | -961.44% | -821.36% | -698.39% | -1089.8% | -513.39% | - | - | - | -28.52% | - | - |
| Operating CF Growth % | 128.48% | 36.26% | -28.75% | -99.11% | -5.84% | 30.36% | -13.87% | 17.38% | -112.52% | -53.74% | -42.14% | -21.67% | 25.11% | 2.91% | -55.25% | -37.99% | -129.24% | 63.59% | -5.74% | 53.4% | -4.81% | -44.25% | -18.63% | -325.03% | -204.67% | 29.94% | -14.06% | -146.45% | 22.93% | 58.44% | -30.22% |
| Net Income | -43.08M | -48.59M | -61.84M | -35.38M | -26.66M | -25.14M | -26.58M | -42.03M | -35.9M | -12.73M | -11.55M | -5.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation & Amortization | 2.2M | 2.04M | 1.13M | 632K | 568K | 969K | 715K | 465K | 384.75K | 109.96K | 140.18K | 62.52K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.24M | 9.52M | 13.5M | 8.38M | 7M | 6.33M | 5.66M | 16.59M | 2.78M | 0 | 1.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -184.51K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.46M | 2.4M | 2.96M | -5.07M | 1.21M | 1.53M | 1.66M | 895K | 706.56K | 495.83K | 160.19K | 377.79K | -4.87M | -6.51M | -6.7M | -4.32M | -3.13M | -1.36M | -3.75M | -3.54M | -7.6M | -7.26M | -5.03M | -4.24M | -997.61K | -327.44K | -467.41K | -409.81K | -166.28K | -215.74K | -519.14K |
| Working Capital Changes | 3.96M | 3.44M | -4.68M | -6.57M | -1.2M | -1.73M | -7.36M | 1.33M | 4.68M | -830.71K | 1.23M | -560.2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Receivables | 1.47M | 3.63M | -4.17M | -3.3M | -985K | -1.19M | -4.98M | -582K | 2.82M | -1.89M | -49.21K | -385.38K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 1.86M | -468K | -2.16M | -3.69M | -371K | -144K | -745K | -468K | 24.31K | -93.97K | 334.28K | -579.58K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -704K | 2.75M | 340K | 809K | 282K | 0 | -1.33M | 2.31M | 98.69K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 600K | 12.45M | 37.36M | 1.61M | -19.33M | -50.21M | -1.17M | -847K | -1.84M | -364.87K | 192.26K | 0 | -22.26K | -62.39K | -70.52K | -78.31K | -95.4K | -59.93K | -53.44K | -130.48K | -59.38K | -94.83K | -349.47K | -103.29K | -487.43K | -276.11K | -1.26M | 0 | 71.39K | 275.24K | 406.19K |
| Capital Expenditures | 618K | -1M | -9.17M | -1.38M | -452K | -487K | -894K | -590K | -1.84M | -364.87K | -425.98K | 0 | -22.54K | -66.82K | -70.52K | -78.31K | -95.4K | -59.93K | -56.95K | -103.25K | -67.8K | -99.96K | 0 | -103.29K | -14.52K | -4.14K | -3.94K | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | 0.82% | 1.4% | 14.27% | 2.75% | 1.31% | 1.47% | 3.06% | 4.14% | 23.45% | 21.4% | 27.63% | - | 2.29% | 2.49% | 2.51% | 2.34% | 2.86% | 2.61% | 2.41% | 8.58% | 8.57% | 11.32% | - | 26.55% | 7.47% | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41.8K | 0 | 0 | 0 | 0 | -874.47K | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.73M | -734K | -162K | -66K | -73K | -49.72M | -280K | -257K | 0 | 0 | 0 | 0 | 281 | 4.42K | 0 | 0 | 0 | 0 | 3.52K | -69.03K | 8.42K | 5.14K | -349.47K | 0 | 1.35K | 0 | -54.4K | 0 | 0 | 0 | 0 |
| Cash from Financing | 20.55M | 14.94M | 3.51M | 40.37M | 900K | 64.06M | 64.05M | 77.06M | 42.49M | 21.29M | 8.11M | 0 | 3.27M | 0 | 8.21M | -98.29K | 13.86M | 1.58M | -170.52K | -9.68K | 9.19M | 5.11M | 8.62M | 3.38M | 289.24K | 632.64K | 2.39M | 1.73M | 0 | 0 | 0 |
| Debt Issued (Net) | 6.1M | 0 | 0 | 38.76M | 0 | -11K | -11K | -42K | -88.68K | -60.98K | 0 | - | - | - | - | - | 214.81K | 201.61K | -299.55K | -12.39K | - | -5.29K | -2.8K | -52.85K | -3.81K | 23.18K | - | - | - | - | - |
| Equity Issued (Net) | 14.02M | 14.14M | 0 | 0 | 0 | 0 | 69.11M | 81.7M | 42.25M | 22.78M | 8.41M | - | 3.6M | - | 8.77M | -96.04K | 14.07M | 1.42M | - | 2.72K | 9.9M | 5.48M | 8.89M | 3.58M | 408.38K | 609.47K | 2.47M | 1.73M | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -96.04K | -232.73K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 433.06K | 795K | 3.51M | 1.61M | 900K | 64.08M | -5.05M | -4.6M | 329.7K | -1.43M | -298.88K | 0 | -335.6K | 0 | -568.26K | -2.25K | -430.46K | -35.81K | 129.04K | 0 | -710.1K | -364.86K | -263.37K | -150.97K | -115.33K | 0 | -77.29K | 0 | 0 | 0 | 0 |
| Net Change in Cash | -3.08M | -3.81M | -8.07M | 3.95M | -37.55M | 37.11M | 37.11M | 53.47M | 13.43M | 8.07M | -254.1K | 0 | -397.69K | -6.16M | 2.01M | -4.6M | 10.06M | 278.4K | -3.22M | -3.53M | 2.68M | -368.06K | 3.24M | 308.82K | -757.7K | 189.39K | 863.98K | 1.32M | -30.01K | 59.5K | -7.09K |
| Free Cash Flow | -23.59M | -32.93M | -58.27M | -39.46M | -19.61M | -18.52M | -27.07M | -23.59M | -29.63M | -13.32M | -8.85M | 0 | -3.76M | -6.19M | -6.19M | -4.5M | -3.44M | -1.22M | -3.08M | -3.58M | -6.52M | -5.48M | -5.03M | -3.07M | -574.03K | -171.29K | -318.69K | -409.81K | -101.4K | -215.74K | -413.29K |
| FCF Margin % | -31.2% | -45.99% | -90.69% | -78.69% | -56.99% | -56.09% | -92.62% | -165.42% | -378.43% | -781.43% | -574.23% | - | -381.45% | -230.77% | -219.75% | -134.11% | -103.08% | -53.11% | -130.18% | -297.15% | -824.04% | -620.8% | -698.39% | -788.48% | -295.41% | - | - | - | -17.39% | - | - |
| FCF Growth % | 43.88% | 43.48% | -47.68% | -101.16% | -5.89% | 31.58% | -14.75% | 20.37% | -122.43% | -50.47% | - | 100% | 39.28% | -0.1% | -37.6% | -30.74% | -181.94% | 60.42% | 13.85% | 45.13% | -18.85% | -9.03% | -63.96% | -434.43% | -235.13% | 46.25% | 22.23% | -304.15% | 53% | 47.8% | -39.27% |
| FCF per Share | -0.77 | -1.18 | -2.25 | -1.56 | -0.78 | -0.76 | -1.33 | -1.16 | -1.33 | -1.43 | -1.32 | - | -1.06 | -1.90 | -2.06 | -1.89 | -1.87 | -0.96 | -2.79 | -5.06 | -1.65 | -2.12 | -0.13 | -1.93 | -0.71 | -0.09 | -0.17 | -0.67 | -0.41 | -4.58 | -8.77 |
| FCF Conversion (FCF/Net Income) | 0.55x | 0.64x | 0.79x | 1.07x | 0.72x | 0.72x | 0.97x | 0.54x | 0.77x | 0.55x | 0.56x | 0.58x | 0.62x | 1.26x | 0.83x | 0.57x | 1.50x | 0.27x | 0.91x | 0.30x | 0.60x | 0.82x | 0.71x | 0.85x | 0.65x | 0.29x | 0.30x | 0.50x | 0.30x | 0.09x | -2.81x |
| Interest Paid | -2.48M | 4.98M | 5.36M | 1.14M | 15K | 29K | 3K | 42K | 27K | 0 | 0 | - | 13 | 25.68K | 91 | 67 | 12.07K | 29.47K | 74.1K | 27.83K | - | 6.54K | - | 14.24K | - | 7 | 67 | - | - | - | - |
| Taxes Paid | 0 | 0 | 41K | 44K | 17K | 0 | 42K | 0 | 0 | 0 | 0 | - | -1.52M | -129.31K | -90.12K | -85.52K | -91.97K | -296.81K | -126.86K | -604.06K | -420.35K | -390K | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying RCEL stock.
Avita Medical Inc. (RCEL) generated $-31.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Avita Medical Inc. (RCEL) reported negative free cash flow of $32.9M in 2025, indicating capital requirements exceeded cash from operations.
Avita Medical Inc. (RCEL) spent $1.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Insufficient liquidity for operations
Metrics are mathematically derived from official filings.
Earnings Quality Remains Severely Disconnected
According to recent quarterly filings, RCEL's operating cash flow frequently tracks closely with net losses, with an OCF/NI ratio that has fluctuated between 0.40 and 1.54, indicating that the company's cash burn is driven primarily by fundamental operating losses rather than temporary working capital timing differences.
The lack of a consistent, positive relationship between net income and operating cash flow suggests that the business model has yet to achieve the scale necessary to decouple cash outflows from revenue generation. Investors should monitor this conversion gap, as it implies that the company's current accounting losses are a direct reflection of its underlying cash-consuming commercial strategy.
Persistent Free Cash Flow Deficits
As reported in financial statements, RCEL has consistently generated negative free cash flow, with quarterly margins reaching as low as -199.0% in 2024Q1, highlighting a structural inability to fund its aggressive commercial expansion through internal operations without relying on external capital infusions to sustain the business.
The trajectory of free cash flow remains deeply negative, suggesting that the company is currently in a high-intensity investment phase that shows little sign of near-term stabilization. This persistent cash drain warrants further investigation into whether the current sales force expansion will eventually yield the operating leverage required to reach cash flow breakeven.
Volatile Working Capital Management Trends
Based on the provided data, working capital changes have been highly erratic, swinging from a $4.0M inflow in 2025Q4 to a $2.2M outflow in 2026Q1, which suggests that the company's cash position is susceptible to significant fluctuations based on the timing of inventory procurement and hospital account collections.
These swings in working capital appear to reflect the challenges of managing a transactional, kit-based revenue model across a growing number of hospital accounts. The inconsistency in these flows may indicate that the company lacks a mature, predictable cycle for managing its receivables and inventory, adding another layer of uncertainty to its liquidity profile.
SBC Masks True Cash Burn
Data from recent filings reveals that stock-based compensation (SBC) has consistently added back millions to the cash flow statement, with quarterly figures reaching as high as $4.1M, which effectively obscures the true economic cost of talent acquisition and retention required to support the company's commercial growth.
While SBC is a non-cash expense, the reliance on equity-based incentives to attract the specialized sales force needed for vitiligo and trauma markets suggests that the company's true operational cost is higher than the reported cash burn implies. Investors should consider the dilutive impact of these compensation packages as a hidden cost of the current growth strategy.